ASCO 2019 | PEACE III: radium-223 vs. enzalutamide for mCRPC

Bertrand Tombal

Bertrand Tombal, MD, PhD, of the Cliniques Universitaires Saint-Luc, Brussels, Belgium, discusses the results of the PEACE III (NCT02194842) trial investigating Radium-223 vs. enzalutamide for metastatic bone dominant castration-resistant prostate cancer (mCRPC). This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Share this video  
Similar topics